Company Filing History:
Years Active: 2005
Title: Innovator Spotlight: Ki Sung Kwon and His Revolutionary Pharmaceutical Preparation
Introduction: Ki Sung Kwon is a notable inventor based in Gwacheon-si, South Korea, recognized for his contributions to the field of pharmaceuticals. With a keen focus on innovations that address critical health needs, Kwon has made significant strides in the development of therapeutic solutions for hemophilia A.
Latest Patents: Kwon holds one patent, titled "Pharmaceutical Preparation of Recombinant Factor VIII Lyophilized Without Albumin as a Stabilizer." This patent addresses a paramount challenge in the therapeutic management of hemophilia A. The invention describes a lyophilized preparation of recombinant factor VIII that utilizes a stabilizing mixture comprising L-arginine, L-isoleucine, and L-glutamic acid. This novel approach eliminates the need for human blood-derived albumin, enhancing the stability and effectiveness of the therapeutic preparation.
Career Highlights: Ki Sung Kwon is associated with Korea Greencross Corporation, an organization that plays a crucial role in the production and development of innovative pharmaceutical products. Kwon's expertise in biopharmaceuticals has positioned him as a vital asset within the company, where he focuses on advancing therapies for patients with bleeding disorders.
Collaborations: Throughout his career, Kwon has collaborated with esteemed colleagues, including Sang Hoon Paik and Yong Nam Shin. These partnerships have fostered an environment of innovation, allowing for the exchange of ideas and collaborative efforts aimed at enhancing therapeutic outcomes for patients.
Conclusion: Ki Sung Kwon exemplifies the spirit of innovation in the pharmaceutical industry. His dedication to improving the lives of those affected by hemophilia A through groundbreaking inventions highlights the importance of research and development in creating effective treatments. As he continues to work within Korea Greencross Corporation, his contributions will undoubtedly lead to further advancements in health care.